Document ID: chunk:federal_register_of_legislation:F2023L01747:schedule:1:p13
Version: federal_register_of_legislation:F2023L01747
Segment Type: schedule
Provision Reference: sch 1 (pt 13/31)
Character Range: 41274–45321

INJECTION BP  WZ  MP NP MW PDP            10      0       10
                                                                                                             a  Maxolon                      IL  MP NP            P6084  40      2       10
                                                                                                                                                                         CN6084  CN6084
                                                                                                             a  METOCLOPRAMIDE INJECTION BP  WZ  MP NP            P6084  40      2       10
                                                                                                                                                                         CN6084  CN6084

     [67]               Schedule 1, Part 1, entry for Mirtazapine in the form Tablet 15 mg
     omit:
         a  APO-Mirtazapine  TX  MP NP  C5650     30  5  30

     [68]               Schedule 1, Part 1, entry for Mirtazapine in the form Tablet 30 mg
     omit:
         a  APO-Mirtazapine  TX  MP NP  C5650     30  5  30

     [69]               Schedule 1, Part 1, entry for Mirtazapine in the form Tablet 45 mg
     omit:
         a  APO-Mirtazapine  TX  MP NP  C5650     30  5  30

     [70]               Schedule 1, Part 1, entry for Moclobemide in each of the forms: Tablet 150 mg; and Tablet 300 mg
     omit:
         a  APO-Moclobemide  TX  MP NP  C5650     60  5  60

     [71]               Schedule 1, Part 1, entry for Obinutuzumab
     insert in numerical order in the column headed "Circumstances": C14764

     [72]               Schedule 1, Part 1, entry for Olanzapine in the form Tablet 5 mg (orally disintegrating)
     omit:
            Olanzapine ODT generichealth 5   GQ   MP NP   C5856 C5869      28   5   28

     [73]               Schedule 1, Part 1, entry for Olaparib
     substitute:
Olaparib  Tablet 100 mg  Oral     Lynparza  AP  MP  C12590 C12598 C14741 C14742 C14743 C14760 C14761 C14778   P12590 P14741 P14743 P14761   112  2  56
                                                MP  C12590 C12598 C14741 C14742 C14743 C14760 C14761 C14778   P12598 P14742 P14760 P14778   112  5  56
          Tablet 150 mg  Oral     Lynparza  AP  MP  C12590 C12598 C14741 C14742 C14743 C14760 C14761 C14778   P12590 P14741 P14743 P14761   112  2  56
                                                MP  C12590 C12598 C14741 C14742 C14743 C14760 C14761 C14778   P12598 P14742 P14760 P14778   112  5  56

     [74]               Schedule 1, Part 1, entry for Ondansetron in the form Tablet (orally disintegrating) 4 mg
         (a)           omit:
            APO-Ondansetron ODT  TX  MP NP  C5618 C10498  P5618  4  0  4
                                     MP     C5743                4  0  4     C(100)

         (b)           omit:
            APO-Ondansetron ODT  TX  MP NP  C5618 C10498  P10498  10  1  10

     [75]               Schedule 1, Part 1, entry for Ondansetron in the form Tablet 4 mg (as hydrochloride dihydrate)
         (a)           omit:
         a  Ondansetron APOTEX  GX  MP NP  C4118 C10498  P4118  4  0  4
                                    MP     C5778                4  0  4     C(100)

         (b)           omit:
         a  Ondansetron APOTEX  GX  MP NP  C4118 C10498  P10498  10  1  10

     [76]               Schedule 1, Part 1, entry for Ondansetron in the form Tablet (orally disintegrating) 8 mg
         (a)           omit:
            APO-Ondansetron ODT  TX  MP NP  C5618 C10498  P5618  4  0  4
                                     MP     C5743                4  0  4     C(100)

         (b)           omit:
            APO-Ondansetron ODT  TX  MP NP  C5618 C10498  P10498  10  1  10

     [77]               Schedule 1, Part 1, entry for Ondansetron in the form Tablet 8 mg (as hydrochloride dihydrate)
         (a)           omit:
         a  Ondansetron APOTEX  GX  MP NP  C4118 C10498  P4118  4  0  4
                                    MP     C5778                4